SCHEMBL6680902

SCHEMBL6680902

CCCCCCC(C)c1ccccc1C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.59
CA12 O43570 2/20 0.47
CA9 Q16790 2/20 0.47
PRSS1 P07477 1/20 0.47
PRSS2 P07478 1/20 0.47
PRSS3 P35030 1/20 0.47
KDM4E B2RXH2 1/20 0.47
MEN1 O00255 1/20 0.47
RECQL P46063 1/20 0.47
KMT2A Q03164 1/20 0.47
CYSLTR2 Q9NS75 1/20 0.45
CYSLTR1 Q9Y271 1/20 0.45
TSHR P16473 2/20 0.44
LMNA P02545 1/20 0.44
PLK1 P53350 4/20 0.44
PTPN11 Q06124 2/20 0.44
SLC37A4 O43826 1/20 0.43
CNR2 P34972 1/20 0.42
PLK3 Q9H4B4 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6680659 0.98 ALDH1A1 (0.57) ALDH1A1CA12CA9PRSS1PRSS2
Potassium SCHEMBL30050002 0.97 ALDH1A1 (0.56) ALDH1A1CA12CA9PRSS1PRSS2
SCHEMBL6384756 0.94 ALDH1A1 (0.51) ALDH1A1CA12CA9KDM4EMEN1
SCHEMBL6859419 0.87 KMT2A (0.47) ALDH1A1CA12CA9KDM4EMEN1
SCHEMBL9504215 0.87 ALDH1A1 (0.52) ALDH1A1CA12CA9PRSS1PRSS2
SCHEMBL5511949 0.87 ALDH1A1 (0.52) ALDH1A1SLC37A4
SCHEMBL9502958 0.87 ALDH1A1 (0.52) ALDH1A1CA12CA9PRSS1PRSS2
SCHEMBL9615354 0.87 ALDH1A1 (0.52) ALDH1A1CA12CA9PRSS1PRSS2
SCHEMBL1699771 0.87 ALDH1A1 (0.49) ALDH1A1PRSS1PRSS2PRSS3CYSLTR2
SCHEMBL23270712 0.86 LMNA (0.52) ALDH1A1PRSS1PRSS2PRSS3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230147285-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE LOXO ONCOLOGY, INC. 2023-05-11 US disclosed
EP-0985649-B1 Method for producing an aromatic compound having an alkyl group with at least three carbon atoms TORAY INDUSTRIES (JP) 2004-11-24 EP disclosed
US-6462248-B1 THROUGH CONVERSION, ISOMERIZATION AND/OR ADSORPTIVE SEPARATION OF AROMATIC COMPOUNDS TORAY INDUSTRIES, INC. (JP) 2002-10-08 US disclosed
EP-0985649-A2 Method for producing an aromatic compound having an alkyl group with at least three carbon atoms TORAY INDUSTRIES, INC. (JP) 2000-03-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230147285-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE PIK3CA, PIK3R4, PIK3R5 ALDH1A1 3412/4885CA12 4588/4885CA9 4035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.